Dr. Heidi Overton became Trump's FDA pick on August 19 — a White House health policy aide with an MD from the University of New Mexico and a PhD from Johns Hopkins. The job comes with an immediate clock: the FDA is weeks away from completing a formal safety study of mifepristone, the abortion pill that accounted for roughly 65% of US abortions in 2025, with a court-mandated status report due October 7. Overton replaces Marty Makary, who resigned in May after pro-life groups said he was slow-walking the review. Her nomination has drawn praise from HHS Secretary RFK Jr., protests from reproductive rights advocates, and unusual public skepticism from the Republican senator who chairs the committee that will confirm her.

The Pill Is Already on Her Agenda

Pro-life groups want Overton to pull mifepristone from the market entirely.

Mifepristone is the first thing pro-life advocates put on her to-do list. Lila Rose of Live Action called on Overton to "pull the deadly abortion pill from the market" and end mail-order access across the country. Americans United for Life CEO John Mize endorsed her immediately. Their argument: more than 7.5 million Americans have used mifepristone since the FDA approved it, but the FDA approved it based on studies pro-life groups consider inadequate, and the pending safety review is the moment to change that. RFK Jr. praised Overton for her "unwavering commitment to the American people."

But Reproductive Rights Groups Say This Is the Worst-Case Pick

They see her nomination as a direct mechanism for restricting abortion access.

Overton is a direct threat to medication abortion access. She has publicly called for Congress to restrict mifepristone, described it as "abortion-on-demand," and celebrated the Dobbs decision as a "huge victory." Sen. Patty Murray called her "a far-right, anti-abortion extremist who has no business leading the FDA." The stakes are concrete. With the safety study due in September and a live court case already in play, the new FDA chief will almost certainly shape what the agency recommends — including whether it ends the mail-order and telehealth access that expanded under Biden. Reproductive Freedom for All and NOW both issued statements of opposition immediately.

Still, the FDA Can't Afford Another Political Pick

Even the Republican senator who chairs the confirmation process has serious doubts.

The pushback isn't only from Democrats. Sen. Bill Cassidy, the Republican chair of the Senate HELP Committee that will oversee her confirmation, said Overton's "lack of managerial experience does not prepare her well for leading a large organization that is already dealing with staffing and morale issues." He went further: her role in a recent Trump vaccine executive order is "almost disqualifying," he said, because it calls into question whether she'll "stand up for sound science." Some MAHA-aligned advocates are also skeptical — questioning whether she'll push back on the agriculture industry after she reportedly backed a position favorable to Bayer on pesticide policy.

Where This Lands

Pro-life groups say the FDA has spent decades looking away from mifepristone's risks, and that Overton will finally let the evidence lead wherever it goes. Reproductive rights advocates are equally clear: Trump picked Overton specifically to use the pending safety review as the legal mechanism to end medication abortion in states where surgical abortion is already banned. Sen. Cassidy isn't objecting to the policy goal — he's objecting to Overton herself, and whether she can run a battered agency without making Americans trust the FDA even less.

Sources